Human T-cell lymphotropic virus oncoprotein Tax represses TGFβ1 signaling in human T cells via c-Jun activation: A potential mechanism of HTLV-I leukemogenesis

Blood

Volumn 100, Issue 12, 2002, Pages 4129-4138

  Arnulf, Bertrand ^a,b,c,d,e   Villemain, Aude ^a,b,c,d   Nicot, Christophe ^a,b,c,d   Mordelet, Elodie ^a,b,c,d   Charneau, Pierre ^a,b,c,d   Kersual, Joëlle ^a,b,c,d   Zermati, Yaël ^a,b,c,d   Mauviel, Alain ^a,b,c,d   Bazarbachi, Ali ^a,b,c,d   Hermine, Olivier ^a,b,c,d  

^a CNRS   (France)

^b SAINT LOUIS HOSPITAL   (France)

^c NATIONAL CANCER INSTITUTE   (United States)

^d AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

^e HÔPITAL NECKER ENFANTS MALADES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CCAAT ENHANCER BINDING PROTEIN; DNA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; SMAD3 PROTEIN; STRESS ACTIVATED PROTEIN KINASE; TAX PROTEIN; TRANSCRIPTION FACTOR AP 1; TRANSFORMING GROWTH FACTOR BETA1;

ARTICLE; CELL STRAIN HEPG2; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; ENZYME ACTIVITY; GENE REPRESSION; HUMAN; HUMAN CELL; HUMAN T CELL LEUKEMIA VIRUS 1; LEUKEMOGENESIS; LYMPHOCYTE PROLIFERATION; LYMPHOCYTE TRANSFORMATION; ONCOGENE C JUN; PRIORITY JOURNAL; PROTEIN DNA BINDING; PROTEIN PHOSPHORYLATION; T CELL LEUKEMIA; TRANSCRIPTION REGULATION;

EID: 0036891934     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2001-12-0372     Document Type: Article

References (56)

1. Poiesz BJ, Ruscetti FW, Gazdar AF, Bunn PA, Minna JD, Gallo RC. Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T cell lymphoma. Proc Natl Acad Sci U S A. 1980;77:7415-7419.
2. Hermine O, Wattel E, Gessain A, Bazarbachi A. Adult T cell leukemia: A review of established and new treatments. Biodrugs. 1998;10:447-462.
3. Franchini G, Molecular mechanisms of human T cell leukemia/lymphotropic virus type I infection. Blood. 1995;86:3619-3639.
4. Bex F, Yin MJ, Burny A, Gaynor RB. Differential transcriptional activation by human T cell leukemia virus type 1 Tax mutants is mediated by distinct interactions with CREB binding protein and p300. Mol Cell Biol. 1998;18:2392-2405.
5. Harrod R, Tang Y, Nicot C, et al. An exposed KID-like domain in human T cell lymphotropic virus type 1 Tax is responsible for the recruitment of coactivators CBP/p300. Mol Cell Biol. 1998; 15 18:5052-5061.
6. Pozzatti R, Vogel J, Jay G. The human T-lymphotropic virus type I tax gene can cooperate with the ras oncogene to induce neoplastic transformation of cells. Mol Cell Biol. 1990;10:413-417.
7. Grassmann R, Fleckenstein B, Desrosiers RC. Viral transformation of human T lymphocytes. Adv Cancer Res. 1994;63:211-244.
8. Nerenberg M, Hinrichs SH, Reynolds RK, Khoury G, Jay G. The tat gene of human T-lymphotropic virus type 1 induces mesenchymal tumors in transgenic mice. Science. 1987;237:1324-1329.
9. Matsumoto K, Shibata H, Fujisawa JI, et al. Human T cell leukemia virus type 1 Tax protein transforms rat fibroblasts via two distinct pathways. J Virol. 1997;71:4445-4451.
10. Iwai K, Mori N, Oie M, Yamamoto N, Fujii M. Human T cell leukemia virus type 1 Tax protein activates transcription through AP-1 site by inducing DNA binding activity in T cells. Virology. 2001; 279:38-46.
11. Fujii M, Iwai K, Oie M, et al. Activation of oncogenic transcription factor AP-1 in T cells infected with human T cell leukemia virus type 1. AIDS Res Hum Retroviruses. 2000;16:1603-1606.
12. Gupta S, Barrett T, Whitmarsh AJ, et al. Selective interaction of JNK protein kinase isoforms with transcription factors. EMBO J. 1996;15:2760-2770.
13. Fujii M, Sassone-Corsi P, Verma IM. c-fos promoter trans-activation by the tax1 protein of human T cell leukemia virus type I. Proc Natl Acad Sci U S A. 1988;85:8526-8530.
14. Behrens A, Sabapathy K, Graef I, et al. Jun N-terminal kinase 2 modulates thymocyte apoptosis and T cell activation through c-Jun and nuclear factor of activated T cell (NF-AT). Proc Natl Acad Sci U S A. 2001;98:1769-1774.
15. Davis RJ. Signal transduction by the JNK group of MAP kinases. Cell. 2000;103:239-252.
16. Behrens A, Sibilia M, Wagner EF. Amino-terminal phosphorylation of c-Jun regulates stress-induced apoptosis and cellular proliferation. Nat Genet. 1999;21:326-329.
17. Jin DY, Teramoto H, Giam CZ, Chun RF, Gutkind JS, Jeang KT. A human suppressor of c-Jun N-terminal kinase 1 activation by tumor necrosis factor alpha. J Biol Chem. 1997;272:25816-25823.
18. Xu X, Heidenreich O, Kitajima I, et al. Constitutively activated JNK is associated with HTLV-1 mediated tumorigenesis. Oncogene. 1996; 13:135-142.
19. Kim SJ, Kehrl JH, Burton J, et al. Transactivation of the transforming growth factor beta 1 (TGF-beta 1) gene by human T lymphotropic virus type 1 tax: A potential mechanism for the increased production of TGF-beta 1 in adult T cell leukemia. J Exp Med. 1990;172:121-129.
20. Niitsu Y, Urushizaki Y, Koshida Y, et al. Expression of TGF-beta gene in adult T cell leukemia. Blood. 1988;71:263-266.
21. Massague J. TGFbeta signaling: Receptors, transducers, and Mad proteins. Cell. 1996;85:947-950.
22. Massague J, Wotton D. Transcriptional control by the TGF-beta/Smad signaling system. EMBO J. 2000;19:1745-1754.
23. Dennler S, Itoh S, Vivien D, ten Dijke P, Huet S, Gauthier JM. Direct binding of Smad3 and Smad4 to critical TGF beta-inducible elements in the promoter of human plasminogen activator inhibitor-type 1 gene. EMBO J. 1998;17:3091-3100.
24. Itoh S, Ericsson J, Nishikawa J, Heldin CH, ten Dijke P. The transcriptional co-activator P/CAF potentiates TGF-beta/Smad signaling. Nucleic Acids Res. 2000;28:4291-4298.
25. Nakao A, Afrakhte M, Moren A. et al. Identification of Smad7, a TGF-beta inducible antagonist of TGF-beta signalling. Nature. 1997;389:631-635.
26. Kretzschmar M, Doody J, Timokhina I, Massague J. A mechanism of repression of TGF-beta/Smad signaling by oncogenic Ras. Genes Dev. 1999; 13:804-816.
27. Massague J, Chen YG. Controlling TGF-beta signaling. Genes Dev. 2000;14:627-644.
28. Letterio JJ, Roberts AB. Regulation of immune responses by TGF-beta. Annu Rev Immunol. 1998;16:137-161.
29. Lucas PJ, Kim SJ, Melby SJ, Gress RE. Disruption of T cell homeostasis in mice expressing a T cell-specific dominant negative transforming growth factor beta II receptor. J Exp Med. 2000; 191:1187-1196.
30. Yang X, Letterio JJ, Lechleider RJ, et al. Targeted disruption of SMAD3 results in impaired mucosal immunity and diminished T cell responsiveness to TGF-beta. EMBO J. 1999;18:1280-1291.
31. Krause A, Holtmann H, Eickemeier S, et al. Stress-activated protein kinase/Jun N-terminal kinase is required for interleukin (IL)-l -induced IL-6 and IL-8 gene expression in the human epidermal carcinoma cell line KB. J Biol Chem. 1998;273:23681-23689.
32. Mauviel A, Chung KY, Agarwal A, Tamai K, Uitto J. Cell-specific induction of distinct oncogenes of the Jun family is responsible for differential regulation of collagenase gene expression by transforming growth factor-beta in fibroblasts and keratinocytes. J Biol Chem. 1996;271:10917-10923.
33. Naldini L, Blomer U, Gallay P, et al. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science. 1996;272:263-267.
34. Dardalhon V, Herpers B, Noraz N, et al. Lentivirus-mediated gene transfer in primary T cells is enhanced by a central DNA flap. Gene Therapy. 2001;8:190-198.
35. Massague J, Blain SW, Lo RS. TGFbeta signaling in growth control, cancer, and heritable disorders. Cell. 2000;103:295-309.
36. Schiemann WP, Pfeifer WM, Levi E, Kadin ME, Lodish HF. A deletion in the gene for transforming growth factor beta type I receptor abolishes growth regulation by transforming growth factor beta in a cutaneous T cell lymphoma. Blood. 1999;94:2854-2861.
37. Knaus PI, Lindemann D, DeCoteau JF, et al. A dominant inhibitory mutant of the type II transforming growth factor beta receptor in the malignant progression of a cutaneous T cell lymphoma. Mol Cell Biol. 1996;16:3480-3489.
38. Kadin ME, Cavaille-Coll MW, Gertz R, Massague J, Cheifetz S, George D. Loss of receptors for transforming growth factor beta in human T cell malignancies. Proc Natl Acad Sci U S A. 1994;91:6002-6006.
39. Capocasale RJ, Lamb RJ, Vonderheid EC, et al. Reduced surface expression of transforming growth factor beta receptor type II in mitogen-activated T cells trom Sezary patients. Proc Natl Acad Sci U S A. 1995;92:5501-5505.
40. Kurokawa M, Mitani K, Irie K, et al. The oncoprotein Evi-1 represses TGF-beta signalling by inhibiting Smad3. Nature. 1998;394:92-96.
41. Whyte P, Williamson NM, Harlow E. Cellular targets for transformation by the adenovirus E1A proteins. Cell. 1989;56:67-75.
42. Datto MB, Hu PP, Kowalik TF, Yingling J, Wang XF The viral oncoprotein E1A blocks transforming growth factor beta-mediated induction of p21/WAF1/Cip1 and p15/INK4B. Mol Cell Biol. 1997; 17:2030-2037.
43. Mori N, Morishita M, Tsukazaki T, et al. Human T cell leukemia virus type I oncoprotein Tax represses Smad-dependent transforming growth factor beta signaling through interaction with CREB-binding protein/p300. Blood. 2001;97:2137-2144.
44. Bitzer M, von Gersdorff G, Liang D, et al. A mechanism of suppression of TGF-beta/SMAD signaling by NF-kappa B/ReIA. Genes Dev. 2000; 14:187-197.
45. Mori N, Fujii M, Iwai K, et al. Constitutive activation of transcription factor AP-1 in primary adult T-cell leukemia cells. Blood. 2000;95:3915-3921.
46. Benn J, Su F, Doria M, Schneider RJ. Hepatitis B virus HBx protein induces transcription factor AP-1 by activation of extracellular signal-regulated and c-Jun N-terminal mitogen-activated protein kinases. J Virol 1996;70:4978-4985.
47. Diao J, Khine AA, Sarangi F, et al. X protein of hepatitis B virus inhibits Fas-mediated apoptosis and is associated with upregulation of the SAPK/JNK pathway. J Biol Chem. 2000;30:8328-8340.
48. Dennler S, Prunier C, Ferrand N, Gauthier JM, Atfi A. c-Jun inhibits transforming growth factor beta-mediated transcription by repressing Smad3 transcriptional activity. J Biol Chem. 2000;275:28858-28865.
49. Chung KY, Agarwal A, Uitto J, Mauviel A. An AP-1 binding sequence is essential for regulation of the human alpha2(l) collagen (COL1A2) promoter activity by transforming growth factor-beta. J Biol Chem. 1996;271:3272-3278.
50. Verrecchia F, Pessah M, Atfi A, Mauviel A. Tumor necrosis factor-alpha inhibits transforming growth factor-beta/Smad signaling in human dermal fibroblasts via AP-1 activation. J Biol Chem. 2000; 275:30226-30231.
51. Kehrl JH, Wakefield LM, Roberts AB, et al. Production of transforming growth factor beta by human T lymphocytes and its potential role in the regulation of T cell growth. J Exp Med. 1986;163:1037-1050.
52. Dong C, Yang DD, Tournier C, et al. JNK is required for effector T cell function but not for T cell activation. Nature. 2000;405:91-94.
53. Weiss L, Whitmarsh AJ, Yang DD, Rincon M, Davis RJ, Flavell RA. Regulation of c-Jun NH(2)terminal kinase (Jnk) gene expression during T cell activation. J Exp Med. 2000;191:139-146.
54. Sabapathy K, Kallunki T, David JP, Graef I, Karin M, Wagner EF. c-Jun NH(2)-terminal kinase (JNK)1 and JNK2 have similar and stage-dependent roles in regulating T cell apoptosis and proliferation. J Exp Med. 2001;193:317-328.
55. Gill PS, Harrington W, Kaplan MH, et al. Treatment of adult T cell leukemia-lymphoma with a combination of interferon alfa and zidovudine. N Engl J Med. 1995;332:1744-1748.
56. Hermine O, Bouscary D, Gessain A, et al. Brief report: Treatment of adult T cell leukemia-lymphoma with zidovudine and interferon alfa. N Engl J Med. 1995;332:1749-1751.